(AOF) – Novartis lost nearly 1% to 75.05 Swiss francs. Investors do not seem so far convinced by the new strategy of the pharmaceutical laboratory presented this morning. The Basel giant intends to become a “pure player” in medical innovation, ie new prescription treatments. It also intends to strengthen its presence in the United States where it intends to become one of the top five laboratories by 2027. Novartis also intends to be in the “top 3” of pharmaceutical groups in China while maintaining leading positions. in Germany and Japan.
In order to achieve these objectives, the Swiss, in the process of separating from its generic activity, Sandoz, will focus on eight major drug brands.
Cosentyx, Entresto, Zolgensma, Kisqali, Kesimpta, Leqvio, Pluvicto and Scemblix have the potential for maximum sales of several billion dollars, says Novartis.
From a financial point of view, the group expects average annual sales growth of 4% until 2027 and a “core” operating margin above 40% in the medium and long term, compared to 33% in the first half of 2022. .
Finally, Novartis assures that its disciplined allocation of capital will allow it to balance the continuation of investments in the company and the return of capital to our shareholders.
In this regard, the group has already distributed 53 billion dollars to its shareholders between 2017 and 2021.
The AOF information reproduced on Capital.fr is taken from the AOF information service. This information is protected by intellectual property rights held by OPTION FINANCE SAS, publisher of the AOF real-time stock market information service, and its contributors. Consequently, any reproduction, copy, duplication, modification, transfer, redistribution, translation, commercial exploitation or not, creation of a hypertext link or reuse in any way whatsoever of this information is subject to the prior written consent of OPTION. FINANCE SAS and its contributors. AOF can be reached at the following address [email protected] OPTION FINANCE SAS collects its data from the sources it considers the safest. However, subject to its gross negligence, OPTION FINANCES SAS and its contributors do not in any way guarantee the absence of error and defects, even hidden ones, nor the exhaustive nature or the lack of conformity for any use whatsoever of this data and of OPTION FINANCE SAS or one of its contributors, and cannot be held responsible for any delays or interruptions that may affect access to them. The user of the OPTION FINANCE SAS service will use the AOF data at his own risk and must hold OPTION FINANCE SAS and its contributors harmless from any claim resulting from this use.
Receive our latest news
Every morning, the information to remember on the financial markets.